Brief: Onesource Specialty Pharma Says Orbicular Secures Tentative U.S. FDA ANDA Approval For Generic Ozempic
21/04/2026 06:35
April 21 (Reuters) - Onesource Specialty Pharma Ltd ONEO.NS: ORBICULAR SECURES TENTATIVE U.S. FDA ANDA APPROVAL FOR GENERIC OZEMPIC Source text: ID:nBSE9gLGJX Further company coverage: ONEO.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Onesource Specialty Pharma
See all newsIndia's Onesource Specialty Pharma rises most in 2-1/2 months on quarterly profit
Brief: Onesource Specialty Pharma June-Quarter Consol PAT 250 Million Rupees
Brief: Onesource Specialty Pharma Says Co, Formycon AG Announce Strategic Manufacturing Partnership For Biosimilars
Brief: Onesource Specialty Pharma Says Delay In Dr Reddy's Supplies Does Not Materially Impact Co's Operations
Brief: Onesource Specialty Pharma Says USFDA Conducts Routine CGMP Inspection At Onesource SPD Bengaluru